RAM
STOK icon

Readystate Asset Management’s Stoke Therapeutics STOK Stock Holding History

Readystate Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,059
Closed -$922K – 907
2025
Q4 		$922K Buy
+29,059
New +$874K 0.04% 221

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Readystate Asset Management's STOK Position: Q1 2026 in Review

Readystate Asset Management sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 29,059 shares — an estimated $922K sold.

Readystate Asset Management first reported a position in STOK in Q4 2025 and held it in 1 quarter. The position peaked at $922K in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Readystate Asset Management reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Readystate Asset Management sold 29,059 Stoke Therapeutics shares in Q1 2026, an estimated $922K.
  • Readystate Asset Management first reported a position in Stoke Therapeutics in Q4 2025 and held it in 1 quarter.
  • Readystate Asset Management's Stoke Therapeutics position peaked at $922K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.